Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allos CEO resigns

Executive Summary

Allos Therapeutics CEO and CFO Michael Hart will resign his positions following appointment of a successor CEO. During Hart's tenure, Allos received an "approvable" letter for Efaproxyn (efaproxiral) for use as an adjunct to whole brain radiation therapy for the treatment of brain metastases from breast cancer (1"The Pink Sheet" June 7, 2004, p. 6). Hart joined Allos in 1999 as chief financial officer and senior VP-operations. He was promoted to president and CEO in December 2001, and appointed to the board of directors in April 2002...
Advertisement

Related Content

Allos Oncologic Efaproxiral Is “Approvable” Pending Phase III ENRICH Data
Allos Oncologic Efaproxiral Is “Approvable” Pending Phase III ENRICH Data
Advertisement
UsernamePublicRestriction

Register

PS046772

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel